Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 477

1.

Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor.

Hino T, Kamitani T, Sagiyama K, Yamasaki Y, Okamoto I, Tagawa T, Ijichi K, Yamamoto H, Yabuuchi H, Honda H.

Eur J Radiol Open. 2019 Jan 31;6:72-77. doi: 10.1016/j.ejro.2019.01.006. eCollection 2019.

2.

Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer.

Kubo N, Harada T, Shiraishi Y, Nosaki K, Nakagaki N, Takeshita M, Ouchi H, Iwama E, Tanaka K, Okamoto I, Sasaki H, Nakanishi Y.

Anticancer Res. 2019 Feb;39(2):671-677. doi: 10.21873/anticanres.13162.

PMID:
30711944
3.

Classification of tumors by imaging diagnosis and preoperative fine-needle aspiration cytology in 120 patients with tumors in the parapharyngeal space.

Matsuki T, Miura K, Tada Y, Masubuchi T, Fushimi C, Kanno C, Takahashi H, Kamata S, Okamoto I, Miyamoto S, Yamashita T.

Head Neck. 2019 Jan 8. doi: 10.1002/hed.25552. [Epub ahead of print]

PMID:
30620436
4.

Risk Factors of Subsequent Primary Melanomas in Austria.

Müller C, Wendt J, Rauscher S, Sunder-Plassmann R, Richtig E, Fae I, Fischer G, Okamoto I.

JAMA Dermatol. 2018 Dec 19. doi: 10.1001/jamadermatol.2018.4645. [Epub ahead of print]

PMID:
30566178
5.

Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.

Anai S, Iwama E, Yoneshima Y, Otsubo K, Tanaka K, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Dec;126:156-161. doi: 10.1016/j.lungcan.2018.11.002. Epub 2018 Nov 5.

PMID:
30527181
6.

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.

Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K.

Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179.

7.

Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.

Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Nov;125:136-141. doi: 10.1016/j.lungcan.2018.09.014. Epub 2018 Sep 18.

PMID:
30429011
8.

Decision-making for people with dementia and advanced kidney disease: a secondary qualitative analysis of interviews from the Conservative Kidney Management Assessment of Practice Patterns Study.

Scott J, Owen-Smith A, Tonkin-Crine S, Rayner H, Roderick P, Okamoto I, Leydon G, Caskey F, Methven S.

BMJ Open. 2018 Nov 12;8(11):e022385. doi: 10.1136/bmjopen-2018-022385.

9.

Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.

Takada K, Toyokawa G, Azuma K, Takamori S, Jogo T, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

In Vivo. 2018 Nov-Dec;32(6):1541-1550. doi: 10.21873/invivo.11412.

PMID:
30348714
10.

Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients.

Nogami N, Nishio M, Okamoto I, Enatsu S, Suzukawa K, Takai H, Nakagawa K, Tamura T.

Respir Investig. 2019 Jan;57(1):27-33. doi: 10.1016/j.resinv.2018.09.003. Epub 2018 Oct 4.

PMID:
30293944
11.

Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.

Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Cancer Sci. 2018 Dec;109(12):3921-3933. doi: 10.1111/cas.13820. Epub 2018 Nov 13.

12.

Structural and functional analysis of miraculin-like protein from Vitis vinifera.

Ohkura SI, Hori M, Saitoh K, Okuzawa T, Okamoto I, Furukawa N, Shimizu-Ibuka A.

Biochim Biophys Acta Proteins Proteom. 2018 Nov;1866(11):1125-1130. doi: 10.1016/j.bbapap.2018.08.009. Epub 2018 Aug 27.

PMID:
30282610
13.

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.

Takamori S, Takada K, Azuma K, Jogo Y, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Toyokawa G, Hirai F, Tagawa T, Okamoto I, Nakanishi Y, Kawahara A, Akiba J, Oda Y, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5903-5907. doi: 10.21873/anticanres.12934.

PMID:
30275217
14.

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.

Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5897-5901. doi: 10.21873/anticanres.12933.

PMID:
30275216
15.

Prevention of anastomotic leak using an advanced pectoral flap in total pharyngolaryngectomy and free jejunal reconstruction for hypopharyngeal or laryngeal carcinoma.

Kondo T, Tsukahara K, Yoshizawa N, Okamoto I, Motohashi R, Nomoto M, Katsube Y, Yatomi M, Iwasawa T, Hanyu K, Ogawa Y.

Acta Otolaryngol. 2018 Oct;138(10):951-955. doi: 10.1080/00016489.2018.1492152. Epub 2018 Sep 27.

PMID:
30261803
16.

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.

Kimura S, Tanaka K, Harada T, Liu R, Shibahara D, Kawano Y, Nakanishi Y, Okamoto I.

Cancer Sci. 2018 Nov;109(11):3657-3661. doi: 10.1111/cas.13787. Epub 2018 Sep 25.

17.

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.

Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y.

J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18.

PMID:
30240852
18.

Generation of human oogonia from induced pluripotent stem cells in vitro.

Yamashiro C, Sasaki K, Yabuta Y, Kojima Y, Nakamura T, Okamoto I, Yokobayashi S, Murase Y, Ishikura Y, Shirane K, Sasaki H, Yamamoto T, Saitou M.

Science. 2018 Oct 19;362(6412):356-360. doi: 10.1126/science.aat1674. Epub 2018 Sep 20.

PMID:
30237246
19.

Combined Immunofluorescence, RNA FISH, and DNA FISH in Preimplantation Mouse Embryos.

Okamoto I.

Methods Mol Biol. 2018;1861:149-159. doi: 10.1007/978-1-4939-8766-5_12.

PMID:
30218366
20.

Spontaneous and Direct Transformation of N,O-Diaryl Carbamates into N,N'-Diarylureas.

Yamasaki R, Honjo Y, Ito A, Fukuda K, Okamoto I.

Chem Pharm Bull (Tokyo). 2018;66(9):880-884. doi: 10.1248/cpb.c18-00394.

21.

Concomitant Extramedullary Plasmacytoma in the Oropharynx and Hypopharyngeal Squamous Cell Carcinoma.

Sato H, Yoshimasu S, Okamoto I, Shimizu A, Katsube Y, Tanaka H, Tsukahara K.

Case Rep Otolaryngol. 2018 Jul 31;2018:1463218. doi: 10.1155/2018/1463218. eCollection 2018.

22.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J.

J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. [Epub ahead of print]

PMID:
30153097
23.

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.

Ide M, Tanaka K, Sunami S, Asoh T, Maeyama T, Tsuruta N, Nakanishi Y, Okamoto I.

Thorac Cancer. 2018 Nov;9(11):1519-1521. doi: 10.1111/1759-7714.12853. Epub 2018 Aug 28.

24.

Reuse of intermittent catheters: a qualitative study of IC users' perspectives.

Avery M, Prieto J, Okamoto I, Cullen S, Clancy B, Moore KN, Macaulay M, Fader M.

BMJ Open. 2018 Aug 17;8(8):e021554. doi: 10.1136/bmjopen-2018-021554.

25.

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade.

Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I.

Oncotarget. 2018 Jul 17;9(55):30587-30593. doi: 10.18632/oncotarget.25743. eCollection 2018 Jul 17.

26.

Contributions by MC1R Variants to Melanoma Risk in Males and Females.

Wendt J, Mueller C, Rauscher S, Fae I, Fischer G, Okamoto I.

JAMA Dermatol. 2018 Jul 1;154(7):789-795. doi: 10.1001/jamadermatol.2018.1252.

PMID:
29898205
27.

A Case of Septicemia due to Nonocclusive Mesenteric Ischemia Occurring in Induction Chemotherapy.

Tanaka H, Tsukahara K, Okamoto I, Kojima R, Hirasawa K, Sato H.

Case Rep Otolaryngol. 2018 Apr 19;2018:7426819. doi: 10.1155/2018/7426819. eCollection 2018.

28.

Anticancer drug treatment for advanced lung cancer with interstitial lung disease.

Otsubo K, Okamoto I, Hamada N, Nakanishi Y.

Respir Investig. 2018 Jul;56(4):307-311. doi: 10.1016/j.resinv.2018.03.002. Epub 2018 Apr 13. Review.

PMID:
29764748
29.

Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.

Kimura S, Harada T, Ijichi K, Tanaka K, Liu R, Shibahara D, Kawano Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Jun;120:98-107. doi: 10.1016/j.lungcan.2018.04.005. Epub 2018 Apr 5.

PMID:
29748024
30.

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study.

Vansteenkiste J, Reungwetwattana T, Nakagawa K, Cho BC, Dols MAC, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam S.

Ann Oncol. 2017 Nov 1;28(suppl_10). doi: 10.1093/annonc/mdx782. No abstract available.

PMID:
29718073
31.

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.

Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, Shinkai M, Hodge RA, Uchida H, Hida T.

Cancer Sci. 2018 Jun;109(6):1930-1938. doi: 10.1111/cas.13623. Epub 2018 May 31.

32.

Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.

Shibahara D, Tanaka K, Iwama E, Kubo N, Ota K, Azuma K, Harada T, Fujita J, Nakanishi Y, Okamoto I.

J Thorac Oncol. 2018 Jul;13(7):926-937. doi: 10.1016/j.jtho.2018.03.012. Epub 2018 Mar 27.

PMID:
29596910
33.

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.

Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E, Tanaka K, Oda Y, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Apr;118:36-40. doi: 10.1016/j.lungcan.2018.01.024. Epub 2018 Feb 2.

PMID:
29572000
34.

Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.

Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, Okamoto T, Yoneshima Y, Okamoto I, Shimokawa M, Oda Y, Nakanishi Y, Maehara Y.

Surg Oncol. 2018 Mar;27(1):88-94. doi: 10.1016/j.suronc.2018.01.002. Epub 2018 Jan 9.

PMID:
29549910
35.

Germline Variants in the POT1-Gene in High-Risk Melanoma Patients in Austria.

Müller C, Krunic M, Wendt J, von Haeseler A, Okamoto I.

G3 (Bethesda). 2018 May 4;8(5):1475-1480. doi: 10.1534/g3.117.300394.

36.

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, Yamamoto N, Ohe Y, Nakagawa K, Fukuoka M.

Lung Cancer. 2018 Mar;117:14-19. doi: 10.1016/j.lungcan.2018.01.005. Epub 2018 Jan 9.

37.

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.

Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M.

Jpn J Clin Oncol. 2018 Apr 1;48(4):367-375. doi: 10.1093/jjco/hyy016.

38.

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers.

Shimada R, Tsukahara K, Takase S, Okamoto I, Sato H, Katsube Y, Maruyama R, Shimizu A.

Jpn Clin Med. 2018 Jan 29;9:1179670717749231. doi: 10.1177/1179670717749231. eCollection 2018.

39.

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.

Iwama E, Nakanishi Y, Okamoto I.

Expert Rev Anticancer Ther. 2018 Mar;18(3):267-276. doi: 10.1080/14737140.2018.1432356. Epub 2018 Jan 27. Review.

PMID:
29363369
40.

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.

Kiura K, Yoh K, Katakami N, Nogami N, Kasahara K, Takahashi T, Okamoto I, Cantarini M, Hodge R, Uchida H.

Cancer Sci. 2018 Apr;109(4):1177-1184. doi: 10.1111/cas.13511. Epub 2018 Feb 27.

41.

Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.

Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Jan;115:116-120. doi: 10.1016/j.lungcan.2017.11.018. Epub 2017 Nov 22.

PMID:
29290251
42.

Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.

Takamori S, Toyokawa G, Okamoto I, Takada K, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.

Anticancer Res. 2018 Jan;38(1):553-557.

PMID:
29277823
43.

Metastatic Lung Adenocarcinoma Mimicking Meningioma.

Yanagihara T, Seki N, Hiwatashi A, Arimura K, O Suzuki S, Okamoto I.

Intern Med. 2018 Apr 1;57(7):1057-1058. doi: 10.2169/internalmedicine.9472-17. Epub 2017 Dec 21. No abstract available.

44.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

45.

CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.

Kawano Y, Iwama E, Tsuchihashi K, Shibahara D, Harada T, Tanaka K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Lung Cancer. 2017 Nov;113:72-78. doi: 10.1016/j.lungcan.2017.09.008. Epub 2017 Sep 14.

PMID:
29110853
46.

Contribution of epigenetic landscapes and transcription factors to X-chromosome reactivation in the inner cell mass.

Borensztein M, Okamoto I, Syx L, Guilbaud G, Picard C, Ancelin K, Galupa R, Diabangouaya P, Servant N, Barillot E, Surani A, Saitou M, Chen CJ, Anastassiadis K, Heard E.

Nat Commun. 2017 Nov 3;8(1):1297. doi: 10.1038/s41467-017-01415-5.

47.

Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer.

Otsubo K, Seki N, Nakanishi Y, Okamoto I.

Ann Oncol. 2018 Mar 1;29(3):780-781. doi: 10.1093/annonc/mdx700. No abstract available.

PMID:
29088405
48.

Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay.

Ota K, Harada T, Otsubo K, Fujii A, Tsuchiya Y, Tanaka K, Okamoto I, Nakanishi Y.

Oncotarget. 2017 Jul 25;8(42):72127-72132. doi: 10.18632/oncotarget.19552. eCollection 2017 Sep 22.

49.

Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups.

Yabuuchi H, Kawanami S, Iwama E, Okamoto I, Kamitani T, Sagiyama K, Yamasaki Y, Honda H.

Radiology. 2018 Feb;286(2):685-695. doi: 10.1148/radiol.2017162204. Epub 2017 Oct 23.

PMID:
29059037
50.

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.

Kato T, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Tao L, Yu W, Khaznadar T, Tajima K, Shibata M, Seki A, Yamamoto N.

Drug Saf. 2018 Feb;41(2):229-237. doi: 10.1007/s40264-017-0596-0.

Supplemental Content

Loading ...
Support Center